The Clinigen team has the expertise, dedication, and drive to successfully navigate the complexities and challenges that can impact patients, healthcare professionals, pharmaceutical and biotechnology companies, and clinical researchers.
James has worked in the Clinigen business for 15 years, moving from the United Kingdom to the United States in 2008 to establish the local clinical trial business. After a decade in clinical trials services, James worked in the unlicensed medicine business, as well as in corporate development, where he worked on market development and the acquisition and integration of CSM and Proleukin® (aldesleukin).
Today James works in the commercial medicines business, overseeing Clinigen activities in cell therapy. This is central to Clinigen's ongoing partnerships to explore use of interleukin-2 (IL-2) with pharmaceutical companies, academic investigators, and researchers to ensure they can access the only IL-2 approved by the United States Food and Drug Administration (FDA) for use as a human medicine. Clinigen also partners with scientific and medical communities that are investigating Proleukin across a wide variety of indications, regimens, and therapeutic approaches.
Dr. Welgemoed is a qualified physician with 17 years of clinical expertise and over 20 years of pharmaceutical experience. Dr. Welgemoed’s clinical background is general medicine with a special interest in hematology-oncology, infectious disease immunology, and rare disease.
Throughout his career, Dr. Welgemoed has fulfilled various roles across commercial, new business development, and medical affairs globally. For the past 5 years, Dr. Welgemoed has been based in the United Kingdom, serving as the global director of Medical Affairs for the Clinigen Group.